Latest Content

A novel combination therapy enhances the effectiveness of proteasome inhibitors against acute myeloid leukemia (AML), improving survival rates in preclinical models.

A study reveals promising results for combining enfortumab vedotin and pembrolizumab in treating recurrent head and neck cancer, showing a 39% response rate.

Patients with fatty liver disease are significantly more likely to develop kidney stones, a national study found.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

A targeted therapy combination achieved complete remission in a CAR-positive PTCL patient post-CAR T-cell therapy for multiple myeloma.

LAG-3 expression appears to be significantly elevated in patients with small cell lung cancer (SCLC).

Health care workers face significant financial hardships, including food insecurity and housing instability, impacting retention and patient care quality.

Ken Cohen, MD, FACP, discusses how clinicians can support patients after a cognitive screening to identify meaningful next steps.